Table A5. Laboratory with SurePath cytological technology (Hvidovre/Frederiksberg Municipality)a.
| Phase 3 vs phase 2 | Phase 4 vs phase 3 | Phase 5 vs phase 4 | |
|---|---|---|---|
| Change in the technology | SurePath LBC | FocalPoint Slide Profiler cutoff decreased to 25%, HC2 triage of ASCUS | FocalPoint GS Imaging System |
| Same technology in both phases | FocalPoint Slide Profiler 50% cutoff, cytology triage of ASCUS | SurePath LBC | SurePath LBC, FocalPoint Slide Profiler 25% cutoff, HC2 triage of ASCUS |
| 23–59 years | 17 634/9385 | 7018/17 634 | 4794/7018 |
| ⩾ASCUS | 830/361, 1.22 (1.08–1.38) | 420/830, 1.27 (1.13–1.43) | 352/420, 1.23 (1.07–1.41) |
| CIN2 | 77/26, 1.58 (1.01–2.46) | 51/77, 1.66 (1.17–2.37) | 39/51, 1.12 (0.74–1.70) |
| ⩾CIN3 | 195/97, 1.07 (0.84–1.36) | 107/195, 1.38 (1.09–1.74) | 80/107, 1.09 (0.82–1.46) |
| CIN treatments | 304/134, 1.21 (0.99–1.48) | 169/304, 1.40 (1.16–1.68) | 140/169, 1.21 (0.97–1.51) |
| <CIN2 | 239/113, 1.13 (0.90–1.41) | 105/239, 1.10 (0.88–1.39) | 122/105, 1.70 (1.31–2.20) |
| False positive for ⩾CIN2 | 558/238, 1.25 (1.07–1.45) | 262/558, 1.18 (1.02–1.36) | 233/262, 1.30 (1.10–1.55) |
| False positive for ⩾CIN3 | 635/264, 1.28 (1.11–1.47) | 313/635, 1.24 (1.08–1.41) | 272/313, 1.27 (1.09–1.49) |
| PPV for ⩾CIN2 | 33%/34%, 0.96 (0.81–1.14) | 38%/33%, 1.15 (0.98–1.34) | 34%/38%, 0.90 (0.74–1.09) |
| PPV for CIN3 | 23%/27%, 0.87 (0.71–1.08) | 25%/23%, 1.08 (0.88–1.33) | 23%/25%, 0.89 (0.69–1.15) |
| 23–29 years | 4949/2413 | 1909/4949 | 1238/1909 |
| ⩾ASCUS | 367/133, 1.35 (1.11–1.63) | 174/367, 1.23 (1.03–1.46) | 135/174, 1.20 (0.97–1.48) |
| CIN2 | 45/19, 1.15 (0.68–1.97) | 21/45, 1.21 (0.72–2.03) | 24/21, 1.76 (0.99–3.15) |
| ⩾CIN3 | 97/36, 1.31 (0.90–1.92) | 56/97, 1.50 (1.08–2.07) | 37/56, 1.02 (0.68–1.53) |
| CIN treatments | 156/55, 1.38 (1.02–1.87) | 81/156, 1.35 (1.03–1.75) | 66/81, 1.26 (0.92–1.73) |
| <CIN2 | 92/30, 1.50 (0.99–2.25) | 34/92, 0.96 (0.65–1.41) | 38/34, 1.72 (1.09–2.72) |
| False positive for ⩾CIN2 | 225/78, 1.41 (1.09–1.81) | 97/225, 1.12 (0.89–1.41) | 74/97, 1.18 (0.88–1.58) |
| False positive for ⩾CIN3 | 270/97, 1.36 (1.08–1.70) | 118/270, 1.13 (0.92–1.40) | 98/118, 1.28 (0.99–1.66) |
| PPV for ⩾CIN2 | 39%/41%, 0.94 (0.74–1.19) | 44%/39%, 1.14 (0.93–1.41) | 45%/44%, 1.02 (0.80–1.31) |
| PPV for CIN3 | 26%/27%, 0.98 (0.70–1.35) | 32%/26%, 1.22 (0.92–1.60) | 27%/32%, 0.85 (0.60–1.21) |
| 30–44 years | 7225/3683 | 3071/7225 | 2164/3071 |
| ⩾ASCUS | 334/136, 1.25 (1.03–1.52) | 176/334, 1.24 (1.04–1.48) | 151/176, 1.22 (0.99–1.50) |
| CIN2 | 31/5, 3.16 (1.23–8.12) | 28/31, 2.12 (1.28–3.54) | 13/28, 0.66 (0.34–1.27) |
| ⩾CIN3 | 82/44, 0.95 (0.66–1.37) | 50/82, 1.43 (1.01–2.03) | 42/50, 1.19 (0.79–1.79) |
| CIN treatments | 129/55, 1.20 (0.87–1.64) | 85/129, 1.55 (1.18–2.03) | 67/85, 1.12 (0.82–1.53) |
| <CIN2 | 94/42, 1.14 (0.79–1.64) | 49/94, 1.23 (0.87–1.73) | 60/49, 1.74 (1.20–2.52) |
| False positive for ⩾CIN2 | 221/87, 1.29 (1.01–1.65) | 98/221, 1.04 (0.83–1.32) | 96/98, 1.39 (1.05–1.83) |
| False positive for ⩾CIN3 | 252/92, 1.40 (1.10–1.77) | 126/252, 1.18 (0.95–1.45) | 109/126, 1.23 (0.96–1.58) |
| PPV for ⩾CIN2 | 34%/36%, 0.94 (0.72–1.23) | 44%/34%, 1.31 (1.05–1.64) | 36%/44%, 0.82 (0.63–1.07) |
| PPV for CIN3 | 25%/32%, 0.76 (0.56–1.03) | 28%/25%, 1.16 (0.86–1.56) | 28%/28%, 0.98 (0.69–1.39) |
| 45–59 years | 5460/3289 | 2038/5460 | 1392/2038 |
| ⩾ASCUS | 129/92, 0.84 (0.65–1.10) | 70/129, 1.45 (1.09–1.94) | 66/70, 1.38 (0.99–1.92) |
| CIN2 | 1/2, 0.30 (0.03–3.32) | 2/1, 5.36 (0.49–59.06) | 2/2, 1.46 (0.21–10.38) |
| ⩾CIN3 | 16/17, 0.57 (0.29–1.12) | 1/16, 0.17 (0.02–1.26) | 1/1, 1.46 (0.09–23.39) |
| CIN treatments | 19/24, 0.48 (0.26–0.87) | 3/19, 0.42 (0.13–1.43) | 7/3, 3.42 (0.88–13.19) |
| <CIN2 | 53/41, 0.78 (0.52–1.17) | 22/53, 1.11 (0.68–1.82) | 24/22, 1.60 (0.90–2.84) |
| False positive for ⩾CIN2 | 112/73, 0.92 (0.69–1.24) | 67/112, 1.60 (1.19–2.16) | 63/67, 1.38 (0.98–1.93) |
| False positive for ⩾CIN3 | 113/75, 0.91 (0.68–1.21) | 69/113, 1.64 (1.22–2.20) | 65/69, 1.38 (0.99–1.92) |
| PPV for ⩾CIN2 | 13%/21%, 0.64 (0.35–1.16) | 4%/13%, 0.33 (0.10–1.07) | 5%/4%, 1.06 (0.22–5.07) |
| PPV for CIN3 | 12%/18%, 0.67 (0.36–1.26) | 1%/12%, 0.12 (0.02–0.85) | 2%/1%, 1.06 (0.07–16.61) |
Abbreviations: ASCUS=atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; HC2=Hybrid Capture 2; PPV=positive predictive value; triage=in case of ASCUS at age ⩾30 years.
Bold signifies significant change comparing the two phases.
a
Comparison of outcomes, by age group and phase.